NCT04766086View on ClinicalTrials.gov

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

PHASE2CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

August 12, 2022

Primary Completion Date

April 27, 2023

Study Completion Date

April 27, 2023

Conditions
Group B Streptococcus Infections
Interventions
BIOLOGICAL

Multivalent Group B streptococcus vaccine

Multivalent Group B streptococcus vaccine

BIOLOGICAL

Tetanus, diphtheria, and acellular pertussis vaccine

Tetanus, diphtheria, and acellular pertussis vaccine

BIOLOGICAL

Placebo

Saline control

Trial Locations (12)

27609

Accellacare - Raleigh, Raleigh

28401

Accellacare - Wilmington, Wilmington

37909

Alliance for Multispecialty Research, LLC, Knoxville

45419

PriMED Clinical Research, Dayton

45429

PriMed Clinical Research, Dayton

67114

Alliance for Multispecialty Research, LLC, Newton

68114

Quality Clinical Research, Inc, Omaha

73112

Lynn Health Science Institute, Oklahoma City

76135

Benchmark Research, Fort Worth

77081

DM Clinical Research - Brookline, Houston

84121

J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City

89119

Alliance for Multispecialty Research, LLC, Las Vegas

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04766086 - Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women | Biotech Hunter | Biotech Hunter